{"id":"NCT03299244","sponsor":"Amgen","briefTitle":"Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)","officialTitle":"A Multicenter, Multiple-dose, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide (AMG 416) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-05-15","primaryCompletion":"2020-04-08","completion":"2020-04-08","firstPosted":"2017-10-03","resultsPosted":"2021-04-30","lastUpdate":"2021-04-30"},"enrollment":637,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Secondary Hyperparathyroidism","Chronic Kidney Disease"],"interventions":[{"type":"DRUG","name":"Etelcalcetide","otherNames":["AMG 416","Parsabiv®"]},{"type":"DRUG","name":"Cinacalcet","otherNames":["Sensipar®","Mimpara®"]}],"arms":[{"label":"Cinacalcet","type":"ACTIVE_COMPARATOR"},{"label":"Etelcalcetide","type":"EXPERIMENTAL"}],"summary":"The primary objective is to demonstrate that treatment with etelcalcetide (AMG 416) is not inferior to treatment with cinacalcet for lowering serum intact parathyroid hormone (PTH) levels by \\> 30% from baseline among participants with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT) who require management with hemodialysis.","primaryOutcome":{"measure":"Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis Intact Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority Analysis","timeFrame":"Baseline and the efficacy assessment phase (EAP; defined as weeks 20 to 27, inclusive).","effectByArm":[{"arm":"Cinacalcet","deltaMin":66.2,"sd":null},{"arm":"Etelcalcetide","deltaMin":71.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":18},"locations":{"siteCount":90,"countries":["China","Hong Kong","India","Malaysia","South Korea","Taiwan"]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":61,"n":315},"commonTop":["Blood calcium decreased","Muscle spasms","Nausea","Vomiting","Upper respiratory tract infection"]}}